45 results about "Hypoxia reoxygenation" patented technology

The present invention relates to methods of identifying whether a candidate compound is a modulator of an orphan G protein-coupled receptor (GPCR). Preferably the GPCR is human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In some embodiments, overexpression of the GPCR promotes survival of cardiomyocytes. In some embodiments, overexpression of the GPCR rescues cardiomyoctes from hypoxia / reoxygenation induced apoptosis. In some embodiments, the GPCR is down-regulated in individuals with congestive heart failure. Agonists of the invention are envisioned to be useful as therapeutic agents for the treatment of ischemic heart disease, including myocardial infarction, post-myocardial infarction remodeling, and congestive heart failure.

The invention discloses a medicine for treating the acute stage of ischemic apoplexy. It takes salvia miltiorrhiza, red peony root and calamus as raw materials, and is extracted to make an injection according to the different characteristics of each traditional Chinese medicine. The medicine of the invention is used for the acute stage treatment of ischemic apoplexy, and has the functions of promoting blood circulation, removing blood stasis, resolving phlegm and dredging collaterals. The results of clinical trials show that the medicine of the present invention has a good therapeutic effect on cerebral embolism, can significantly increase the local blood flow of the brain, improve the hemiplegia syndrome caused by cerebral embolism, reduce the infarct size in the brain, and reduce cerebral edema and nerve cell secondary Sexual damage; significantly inhibit platelet aggregation and thrombus formation; effectively prolong blood coagulation time; have obvious protective effect on brain neuron damage caused by hypoxia and reoxygenation.

The invention discloses a salidroside-biotin small molecule probe, a preparation method and application thereof, and belongs to the field of medicinal chemistry. The structural formula of the small molecule probe in the present invention includes three parts: salidroside, biotin and connecting chain. The salidroside small-molecule probe designed by the present invention has been tested for in vitro activity, and the results show that it has good activity in protecting the primary cardiomyocyte injury induced by hypoxia-reoxygenation, and can be used as a small-molecule probe for rhodoside The research on the mechanism of action of Tianglycoside has a good application prospect in the medical field.

The invention discloses a pharmaceutical composition, specifically a pharmaceutical composition for treating ischemic cerebral apoplexy. Based on the total weight of the composition, the composition is: lactone components, 18.1-50.9%; flavonoid components , 48.8‑81.8%; organic acid components, 0.07‑6.83%. The pharmaceutical composition of lactone components, flavonoid components and organic acid components and their application in the treatment of ischemic stroke have not been reported in the prior art. The pharmaceutical composition provided by the present invention can effectively reduce the cerebral infarction area of ​​the cerebral ischemia-reperfusion model mouse, and reduce its neurological function score, and can significantly improve the neuronal cell damage in the glucose and oxygen deprivation / hypoxia-reoxygenation neuron cell damage model. The activity of the microglia has a significant protective effect on the inflammation of LPS-induced microglial cells, is safe and effective, and can be prepared as a drug for preventing or treating ischemic stroke.

The invention discloses a triterpenoid saponin compound. The triterpenoid saponin compound is extracted from clematis tangutica and then is subjected to separation and purification. The triterpenoid saponin compound is shown in the formula (I) and comprises an aglycone of 3 beta, 23-dihydroxyolean-18-olefine acid. The triterpenoid saponin compound has obvious effects of protecting anoxic / oxygen-rich model-induced myocardial cell injuries, can be used for preparation of a drug for treating ischemic heart diseases, is a lead compound for researching and preparing a novel drug for treating ischemic heart diseases, and can provide a clinical drug which is used for treating myocardial ischemia / reperfusion injuries and has strong activity and small toxic and side effects.